Aquestive Therapeutics Inc.

1.39+0.2200+18.80%Vol 1.39M1Y Perf -67.95%
Aug 11th, 2022 16:00 DELAYED
BID1.30 ASK1.42
Open1.17 Previous Close1.17
Pre-Market- After-Market1.38
 - -  -0.01 -0.72%
Target Price
6.50 
Analyst Rating
Strong Buy 1.00
Potential %
367.63 
Finscreener Ranking
★★★★+     55.28
Insiders Trans % 3/6/12 mo.
100/100/100 
Value Ranking
★+     43.58
Insiders Value % 3/6/12 mo.
100/100/100 
Growth Ranking
★★     47.28
Insiders Shares Cnt. % 3/6/12 mo.
100/100/100 
Income Ranking
 —    -
Price Range Ratio 52W %
13.35 
Earnings Rating
Strong Buy
Market Cap74.16M 
Earnings Date
2nd Aug 2022
Alpha-0.05 Standard Deviation0.32
Beta3.43 

Today's Price Range

1.151.47

52W Range

0.61806.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
57.95%
1 Month
74.62%
3 Months
29.91%
6 Months
-45.06%
1 Year
-67.95%
3 Years
-65.16%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AQST1.390.220018.80
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
68.40
-94.80
-89.20
-122.70
-91.51
RevenueValueIndustryS&P 500US Markets
36.64M
0.75
-3.11
-6.32
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.41-0.3612.20
Q01 2022-0.45-0.3228.89
Q04 2021-0.37-0.38-2.70
Q03 2021-0.40-0.377.50
Q02 2021-0.42-0.3321.43
Q01 2021-0.44-0.416.82
Q04 2020-0.46-0.60-30.43
Q03 2020-0.50-0.492.00
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.418.89Positive
9/2022 QR-0.3612.20Positive
12/2022 FY-1.3418.29Positive
12/2023 FY-0.74-8.82Negative
Next Report Date-
Estimated EPS Next Report-0.41
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume1.39M
Shares Outstanding53.35K
Shares Float37.06M
Trades Count3.12K
Dollar Volume1.82M
Avg. Volume1.18M
Avg. Weekly Volume2.01M
Avg. Monthly Volume774.25K
Avg. Quarterly Volume758.22K

Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 1.39 per share at the end of the most recent trading day (a 18.8% change compared to the prior day closing price) with a volume of 1.39M shares and market capitalization of 74.16M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.

The one-year performance of Aquestive Therapeutics Inc. stock is -67.95%, while year-to-date (YTD) performance is -64.27%. AQST stock has a five-year performance of %. Its 52-week range is between 0.618 and 6.4, which gives AQST stock a 52-week price range ratio of 13.35%

Aquestive Therapeutics Inc. currently has a PE ratio of -0.50, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 1.11, a price to cashflow ratio of 38.20, a PEG ratio of 2.32, a ROA of -116.65%, a ROC of -107.70% and a ROE of 95.33%. The company’s profit margin is -91.51%, its EBITDA margin is -89.20%, and its revenue ttm is $36.64 Million , which makes it $0.75 revenue per share.

Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.41 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $6.5, which is +367.63% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aquestive Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 18.26, ATR14 : 0.14, CCI20 : 289.14, Chaikin Money Flow : -0.19, MACD : 0.07, Money Flow Index : 89.67, ROC : 72.67, RSI : 64.10, STOCH (14,3) : 88.06, STOCH RSI : 1.00, UO : 51.86, Williams %R : -11.94), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were: A. Mark Schobel (Buy at a value of $44 036), Daniel Barber (Buy at a value of $88 073), Lori J. Braender (Buy at a value of $13 211), Peter Boyd (Buy at a value of $6 251)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aquestive Therapeutics Inc.

Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.

CEO: Keith J. Kendall

Telephone: +1 908 941-1900

Address: 30 Technology Drive, Warren 07059, NJ, US

Number of employees: 232

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

65%35%

Bearish Bullish

67%33%

Bearish Bullish

56%44%

TipRanks News for AQST

Thu, 16 Jun 2022 15:35 GMT Aquestive Therapeutics (AQST) Received its Third Buy in a Row

- TipRanks. All rights reserved.

Wed, 18 May 2022 04:45 GMT Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Logicbio Therapeutics (LOGC)

- TipRanks. All rights reserved.

Wed, 04 May 2022 17:25 GMT Aquestive Therapeutics (AQST) Receives a Buy from JMP Securities

- TipRanks. All rights reserved.

Wed, 04 May 2022 16:37 GMT Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush

- TipRanks. All rights reserved.

Wed, 09 Mar 2022 21:05 GMT Aquestive Therapeutics (AQST) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

News

Stocktwits